In an industrial collaboration project, TU Wien has developed a medication that can alleviate or even completely eliminate the symptoms of celiac disease. It should be available as early as 2021.
Celiac disease is a fairly common disease, affecting one to two percent of the European population. It is expressed as a hypersensitivity to gluten, a protein found in cereals such as wheat, barley or rye.
Although efforts are already being made to treat celiac disease, the proposed drugs have an effect on the immune system. Possible side effects must therefore be examined very carefully. Although initial clinical studies are underway, they will not lead to a marketable product in the next few years.
For this reason, an entirely different approach has been pursued at TU Wien in collaboration with the industrial partner Sciotech Diagnostic Technologies GmbH. Instead of developing a drug that interferes with the immune system, TU Wien has created a simple medical product that directly attacks the gluten molecules to render them harmless. This makes the approval process much simpler, meaning that the product should be available in ordinary pharmacies as early as 2021.
Molecules like keys and locks
“Our bodies produce antibodies that fit intruding antigens precisely, like a key to a lock. This immune response makes these antigens harmless,” explains Professor Oliver Spadiut, head of the Integrated Bioprocess Development Research Group at TU Wien. “If a new antibody fragment is found and produced that docks to and blocks the invading gluten molecule without triggering the immune system, the symptoms of celiac disease can be suppressed.”
The aim of the research project was therefore to produce a complex of two such antibody fragments that envelop the gluten molecule at a molecular level, so that it can no longer have any further effects in the intestines.
To do this, certain bacteria have to be reprogrammed so that they produce exactly the desired antibody fragment. “The formation of such proteins in a bacterium is a highly complicated process,” explains Oliver Spadiut. “It can easily happen that the proteins are not folded exactly as we want.” Instead of the desired antibody fragments, so-called “inclusion bodies” are formed – small particles consisting of incorrectly folded proteins. A process therefore had to be developed to refold these inclusion bodies and to obtain the desired proteins from them.
Such processes, in which the folding of proteins is specifically altered, have not yet been studied in great detail and so they are not very efficient. “You have to precisely understand the chemical processes involved and intervene in a complicated way,” says Oliver Spadiut. “It has therefore taken a while, but we have now developed a process that can be easily reproduced, can be scaled up to industrial application and delivers a very good yield of the desired product”
In pharmacies soon
The project was supported by the industrial partner SCIOTEC Diagnostic Technologies GmbH, who will now bring the new medical product to the market. “It will be a preparation that celiac patients can take together with gluten-containing foods to alleviate coeliac symptoms,” explains Oliver Spadiut. “It remains to be seen whether the symptoms will disappear completely or will only be alleviated. The precise effects will probably vary from person to person.
Learn more: A new remedy for celiac disease
The Latest on: Celiac disease
via Google News
The Latest on: Celiac disease
- Here’s What *Really* Happens to Your Body When You Stop Eating Glutenon August 8, 2020 at 12:04 pm
Three nutrition pros weigh in on who should go gluten-free, its potential benefits, and what happens to your body when you stop eating gluten.
- Celiac Disease Epidemiology Forecast to 2030 - ResearchAndMarkets.comon August 7, 2020 at 8:36 am
The "Celiac Disease (CD) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
- Thiel College grad has honors thesis published on Northeast Regional Honors Conference websiteon August 3, 2020 at 7:43 am
Thiel College 2020 graduate Breanna Mesich recently had her Dietrich Honors Institute thesis published online when the conference where she was scheduled to present her research was canceled due to ...
- Global Celiac Disease Drugs Market 2020 Industry Scenario, Strategies, Growth Factors and Forecast to 2025on August 2, 2020 at 11:16 am
Global Celiac Disease Drugs Market 2020 by Company, Type and Application, Forecast to 2025 is the latest publication from MarketsandResearch.biz which contains insightful data helpful for the decision ...
- Celiac Disease Pipeline Insights 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.comon July 31, 2020 at 1:15 am
Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. Celiac Disease is one of the widely researched conditions ...
- Global Celiac Disease Pipeline Overview and Outlook 2020 Featuring 19 Companies Including Amgen, GlaxoSmithKline and Takeda Pharmaon July 31, 2020 at 1:13 am
The "Celiac Disease Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status ...
- Improved HLA-based prediction of coeliac disease identifies two novel genetic interactionson July 30, 2020 at 9:03 am
The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43–52. Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al. The prevalence of celiac disease in Europe: ...
- Gene variations at birth reveal origins of inflammation and immune diseaseon July 28, 2020 at 11:05 am
A study has pinpointed a number of areas of the human genome that may help explain the neonatal origins of chronic immune and inflammatory diseases of later life, including type 1 diabetes, rheumatoid ...
- Tooth Tales: How Gluten Can Take a Bite Out of Dental Healthon July 28, 2020 at 8:41 am
From pitted tooth enamel to canker sores, oral health may be a sneaky sign of celiac disease. Yet too few dentists are filled in on the risks.
via Bing News